Resultado de búsqueda
22 de feb. de 2022 · GSK announced that its consumer health business will become an independent company named Haleon in mid-2022. Haleon will have a portfolio of global brands, including Sensodyne, Voltaren, Panadol and Centrum, and will list on the London Stock Exchange.
- Sitio Web Global
We are a focused biopharma company with strong momentum and...
- Sitio Web Global
15 de ene. de 2022 · GSK confirms it has received three proposals from Unilever to acquire its Consumer Healthcare business, a JV with Pfizer, but rejected them as undervaluing the business. GSK plans to demerge the business in mid-2022 and create a new global consumer company.
Para lograr eso, hemos desarrollado el portal GSK Pro, para que los profesionales de la salud puedan tener un fácil acceso a todos nuestros recursos, herramientas, consejos, opiniones y noticias. Solicite mayor información de nuestros productos en nuestro servicio de información médica, a través del email: mila@gsk.com. PM-PE-NA-WCNT-230001.
15 de jul. de 2022 · July 15 (Reuters) - British drugmaker GSK (GSK.L) will spin off its consumer health business Haleon worth up to an estimated 48 billion pounds ($57 billion) on Monday in the biggest listing...
GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme. [5]
Somos una compañía biofarmacéutica global con el propósito de juntos, unir ciencia, tecnología y talento para adelantarnos a la enfermedad. Nuestro objetivo es tener un impacto positivo en la salud de 2.500 millones de personas para finales del año 2030.
